Lifecore Biomedical Inc (LFCR) - News Archive

Lifecore Biomedical: Navigating Challenges and Opportunities in the Injectable Pharmaceutical Market Lifecore Biomedical Inc., a prominent player in the biotechnology sector, recently made strides in securing its positi...

Lifecore Biomedical and Nirsum Labs Collaborate on Development of Innovative Opioid Use Disorder Treatment Lifecore Biomedical, a renowned contract development and manufacturing organization (CDMO), has recently been se...

Lifecore Biomedical Enhances Its Operational Foundation with Strategic Leadership Appointment and Capital InfusionIn a series of strategic maneuvers aimed at bolstering its operational capabilities and financial standin...

Lifecore Biomedical Navigates Financial Challenges with Strategic PIPE Investment Despite Recent LossesIn a bold move to bolster its balance sheet and reinforce operational capabilities, Lifecore Biomedical Inc. announc...

for CSIMarket.com In recent months, numerous class action lawsuits have been initiated against various companies, including Lifecore Biomedical, Inc. (NASDAQ: LFCR), Spire Global, Inc. (NYSE: SPIR), DexCom, Inc. (NASDAQ...

New York, September 10, 2024 - Bragar Eagel & Squire, P.C. a law firm recognized nationwide for its expertise in shareholder rights, has issued a reminder to investors regarding pending class action lawsuits on behalf o...

Title for the Objective of the Navigating Legal Challenges: Lifecore Biomedical Faces Shareholder Turbulence and High ROE in Q4 2024In a recent development, Lifecore Biomedical Inc announced the appointment of Brikkelle...

Shareholder Turbulence: Lifecore, Spire Global, Oddity Tech, and Arbor Realty Face Legal Scrutiny It seems these are trying times for investors linked to Lifecore Biomedical, Inc. (NASDAQ: LFCR), Spire Global, Inc. (NYS...

In a rapidly evolving biopharmaceutical landscape, investor awareness and engagement are undeniably critical. As stakeholders in Lifecore Biomedical, Inc. (NASDAQ: LFCR) navigate the complexities of the market, the rece...

Class action lawsuits are an essential component of the shareholder rights landscape, often serving to highlight corporate governance issues, financial misrepresentations, or breaches of fiduciary duty. Recently, Bragar...

Lifecore Biomedical Faces a Class Action Lawsuit: Implications for Investors and the Biopharmaceutical Sector In a significant legal development within the biopharmaceutical sector, Lifecore Biomedical, Inc. (NASDAQ: LF...

In a dynamic pharmaceutical landscape, leadership and strategic direction become key drivers of an organization s success. Lifecore Biomedical s recent cooperation agreement with 22NW, marking the induction of four high...

Lifecore Biomedical Grants Restricted Stock and Performance Stock Unit Awards to Newly Hired CEOCHASKA, Minn., May 22, 2024 - Lifecore Biomedical, Inc. (NASDAQ: LFCR), a fully integrated contract development and manufac...

Lifecore Biomedical Secures $8 Million in Non-Dilutive, Incremental Liquidity through Lender AmendmentsIn a recent move, Lifecore Biomedical, a leading medical device company, has successfully executed a series of incre...

In recent developments, Rosen Law Firm, a prominent global investor rights law firm, has initiated an investigation into potential securities claims on behalf of shareholders of Lifecore Biomedical Inc. (formerly known...

Lifecore Biomedical Concludes Strategic Evaluation Process, Announces Management Succession and Board Changes Lifecore Biomedical, a leading contract development and manufacturing organization (CDMO), has recently concl...

In a recent press release, Lifecore Biomedical, Inc. announced the receipt of a Nasdaq notice of delisting. However, the company also confirmed its intention to appeal, ensuring that the suspension or delisting of its s...

In a significant move aimed at solidifying its longstanding partnership, Lifecore Biomedical has recently entered into a series of commercial agreements with Alcon, a leading global eye care company. These agreements en...

Lifecore Biomedical, Inc. (NASDAQ: LFCR), a leading contract development and manufacturing organization (CDMO) in the pharmaceutical industry, recently provided a business update that indicates turbulent times for the c...